Companies Stand By MS Drug After Illnesses
Monday, August 4, 2008 - 08:56
in Health & Medicine
Biogen Idec Inc. and Elan Corporation defended Tysabri on Friday, saying the treatment is still worth the risk to patients.
Biogen Idec Inc. and Elan Corporation defended Tysabri on Friday, saying the treatment is still worth the risk to patients.